- Reaction score
- 941
HairLossTalk:
How are you? Hope you have been doing well.
Thank you once again for coordinating the interview with the Tsuji team a few months ago.
Some prominent members have asked me to inquire with your team, to see how your efforts to find a solution to the inductivity (functionality) problem is coming along?
To be more specific:
Mr. Toyoshima stated: "For applications of our technology, both mesenchymal stem cells and epithelial stem cells, which are applicable to human clinical applications, are needed. With respect to the development of the technology to cultivate mesenchymal stem cells, that is papilla cells, being applicable to human clinical trials, we are already in progress now for development. On the other hand, as for the technology to cultivate epithelial stem cells of follicles, it still remains a significant challenge globally. We are currently in the middle of research and development for this. Based on our recent research results, we finally have some prospects and expect this issue to be resolved in the near future."
We were interested in learning if you have made any progress with the difficulties of culturing the epithelial stem cells?
Thank you.
----------------
Tsuji Team:
Dear Kevin,
I'm excellent! And you? Long time no see.
Thank you for your interest.
Our research progresses as planned.
First-in-human will start in early-2019 after regulatory notification on our technology as a class 2 regenerative medicine.
Best regards
How are you? Hope you have been doing well.
Thank you once again for coordinating the interview with the Tsuji team a few months ago.
Some prominent members have asked me to inquire with your team, to see how your efforts to find a solution to the inductivity (functionality) problem is coming along?
To be more specific:
Mr. Toyoshima stated: "For applications of our technology, both mesenchymal stem cells and epithelial stem cells, which are applicable to human clinical applications, are needed. With respect to the development of the technology to cultivate mesenchymal stem cells, that is papilla cells, being applicable to human clinical trials, we are already in progress now for development. On the other hand, as for the technology to cultivate epithelial stem cells of follicles, it still remains a significant challenge globally. We are currently in the middle of research and development for this. Based on our recent research results, we finally have some prospects and expect this issue to be resolved in the near future."
We were interested in learning if you have made any progress with the difficulties of culturing the epithelial stem cells?
Thank you.
----------------
Tsuji Team:
Dear Kevin,
I'm excellent! And you? Long time no see.
Thank you for your interest.
Our research progresses as planned.
First-in-human will start in early-2019 after regulatory notification on our technology as a class 2 regenerative medicine.
Best regards